Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rimantadine is a synthetic antiviral small molecule used for the prevention and treatment of infections caused by influenza A virus. It acts primarily by inhibiting an early step in the viral replication cycle, likely interfering with the uncoating process of the virus. This effect is mediated through interaction with the M2 protein (matrix protein 2) of influenza A, which is essential for viral replication. Rimantadine has no significant activity against influenza B viruses and does not interfere with immune responses to inactivated influenza vaccines. It is administered orally as tablets or syrup, but its use has declined due to widespread resistance among circulating strains of influenza A[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rimantadine.